Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F. Navarro-Sarabia, R. Ariza-Ariza, B. Hernandez-Cruz, I. Villanueva.
Adalimumab for treating rheumatoid arthritis.
Cochrane Database Syst Rev, (2005), pp. 20
[2.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, A.F. Kavanaugh, E.K. Chartash, O.G. Segurado.
Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study.
Ann Rheum Dis, 65 (2006), pp. 753-759
[3.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[4.]
G.R. Burmester, I. Monteagudo, M.G. Malaise, S. Kary, H. Kupper.
Adalimumab (HUMIRA) is effective and safe in treating rheumatoid arthritis in real-life clinical practice.
Arthritis Rheum, 52 (2005), pp. S541
[5.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, et al.
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
[6.]
L. Klareskog, D. Van der Heijde, J.P. De Jager, A. Gough, J. Kalden, M. Malaise, et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Lancet, 363 (2004), pp. 675-681
[7.]
M.C. Genovese, A.F. Kavanaugh, S.B. Cohen, P. Emery, E.H. Sasso, G.T. Spencer-Green, et al.
The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA) plus MTX or MTX alone.
Arthritis Rheum, 52 (2005), pp. S451
[8.]
M. Flendrie, M.C. Creemers, P.M. Welsing, A.A. Den Broeder, P.L. Van Riel.
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Ann Rheum Dis, 62 (2003), pp. ii30-ii33
[9.]
BIOBADASER website Disponible en: http://biobadaser.ser.es
[10.]
M. Kishimoto, J. Greenberg, S.B. Abramson, T. Harrington, T. Olengiski, S.P. Kafka, et al.
Drug survival time on anti-TNF agents: does prior anti-TNF use influence RA outcomes?.
Arthritis Rheum, 52 (2005), pp. S347
[11.]
M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med, 353 (2005), pp. 1114-1123
[12.]
S.B. Cohen, M. Greenwald, M.R. Dougados, P. Emery, R. Furie, T.M. Shaw, et al.
Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-alfa therapies (REFLEX study).
Arthritis Rheum, 52 (2005), pp. S677
[13.]
B. Haraoui.
Is there a rationale for switching from one anti-tumor necrosis factor agent to another?.
J Rheumatol, 31 (2004), pp. 1021-1022
[14.]
K.L. Hyrich, A.J. Silman, M. Lunt, K. Watson, D. Smmons.
Influence of response and adverse events rates to a first anti-TNF alfa agent on the outcome from switching to a second agent: results from British Society of Rheumatology biologics register.
Arthritis Rheum, 52 (2005), pp. S339-S340
[15.]
J.J. Gómez-Reino, L. Carmona, The BIOBADASER group.
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Arthritis Res Ther, 8 (2006), pp. R29
[16.]
S.N. Nikas, P.V. Voulgari, Y. Alamanos, C.G. Papadopoulos, A.I. Venetsanopoulou, A.N. Georgiadis, et al.
Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study.
Ann Rheum Dis, 65 (2006), pp. 257-260
[17.]
A.N. Bennett, P. Peterson, A. Zain, J. Grumley, G. Panayi, B. Kirkham.
Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients,including comparison of patients with and without previous anti-TNF exposure.
Rheumatology (Oxford), 44 (2005), pp. 1026-1031
[18.]
M.C. Wick, S. Ernestam, S. Lindblad, J. Bratt, L. Klareskog, R.F. Van Vollenhoven.
Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Scand J Rheumatol, 34 (2005), pp. 353-358
[19.]
S. Bombardieri, A.G. Tzioufas, F. McKenna, U. Ozer, H. Kupper.
Adalimumab (Humira) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life settings.
Arthritis Rheum, 52 (2005), pp. S144
[20.]
D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Birbara, D. Compagnone, et al.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
J Rheumatol, 30 (2003), pp. 2563-2571
[21.]
M.H. Schiff, G.R. Burmester, J.M. Kent, A.L. Pangan, H. Kupper, S.B. Fitzpatrick, et al.
Safety analyses of adalimumab (HUMIRA(R)) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
Ann Rheum Dis, (2006),
Copyright © 2006. Elsevier España S.L. Barcelona
